Regulatory News:
Nordic Nanovector ASA (OSE:NANO), a company focusing on the development
and commercialisation of novel targeted therapeutics in haematology and
oncology announces that Luigi Costa, Chief Executive Officer, will hold
a company presentation at the Swiss Biotech Day in Basel, Switzerland on
Tuesday 12 April 2016.
The slides of the presentation will be available on the day of the
presentation at Nordic Nanovector’s website, in the section Investor
Relations/Reports and Presentations/Presentations/2016.
###
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company’s lead clinical-stage product opportunity is
Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates
(ARC) designed to improve upon and complement current options for the
treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with
substantial unmet medical need and orphan drug opportunities,
representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1)
conjugated to a low intensity radionuclide (lutetium-177). The
preliminary data has shown promising efficacy and safety profile in an
ongoing Phase 1/2 study in a difficult-to-treat NHL patient population.
The Company is aiming at developing Betalutin® for the treatment of
major types of NHL with first regulatory submission anticipated in 1H
2019. Nordic Nanovector intends to retain marketing rights and to
actively participate in the commercialisation of Betalutin® in core
markets, while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline to
treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160407005530/en/
Copyright Business Wire 2016